Of 49 compounds known to have antitumor properties, 6 were found to have significant activity against Trypanosoma rhodesiense infections in mice. Activity against the African trypanosomes has not been reported previously for any of these six compounds. In order of decreasing activity these compounds were: (i) imidazole-4-carboxamide, 5-(3,3-dimethyl-1,1-triazene), (ii) inosine diglycolaldehyde, (iii) cis-diamminedichloro-platinum, (iv) streptozotocin, (v) coralyne sulfate, and (vi) 5-fluoro-2'-deoxyuridine. The percentage of "hits" (12.2%) from these known antitumor agents was approximately twice as great as when other means are employed for the selection of compounds for this test system.
osomes are quite similar to those of some tumor cells (1) . Both undergo a high rate of aerobic glycolysis as a result of inefficient or nonfunctional mitochondrial systems (8) . In each, the key "pacemaking" glycolytic enzymes are hexokinase, phosphofructokinase, and pyruvic kinase (7) . It is known that this metabolic pathway may be altered by agents, including arsenical antitrypanosomal drugs, which are effective against both trypanosomes and tumors (2, 3) . One might suspect that compounds with known anti-trypanosomal properties may have antitumor properties and vice versa. Actually, a number of anti-trypanosomal compounds have been found to be active against experimental tumors (5, 8) ; conversely, a number of antitumor agents have shown anti-trypanosomal effects (4, 8, 9) .
The foregoing encouraged us to examine a selected group of compounds from diverse chemical classes with well-documented capacities to modify the growth of human and/or animal neoplasms. The compounds selected were tested by utilizing a mouse model which employs experimental infections produced by Trypanosoma rhodesiense (6) .
MATERIALS AND METHODS
The test system has been described elsewhere (6) . Briefly, ICR/Ha Swiss mice of either sex, weighing 30 to 32 g, were given an intraperitoneal injection of 0.5 ml of a 1:50,000 dilution of heparinized heart blood drawn from donor mice infected 3 14 days] are known to occur after a single dose of some oncolytic agents, the previously established criteriafor routine screening were followed [6] .) Cures and toxic deaths were not included in calculating the mean survival time of test animals.
Compounds were selected from two listings furnished by the Drug Development Branch, National Cancer Institute (10, 11) . The criterion for selecting these agents with anticancer activity was the availability of the compounds (at least 100 mg) for testing in the T. rhodesiense-mouse model. A total of 49 compounds from these two lists (there was a total of 82 compounds on both lists) met this criterion and are the basis of the present report.
RESULTS
Results for the 6 active compounds of the 49 tested in this study are summaized in Table 1 . The chemical formulas for these are shown in Fig. 1 . Compounds which were inactive against these T. rhodesiense infections are listed in 
DISCUSSION
The present screening of 49 compounds selected from known antineoplastic drugs has shown that 6 possess significant activity against T. rhodesiense. To our knowledge, activity against the African trypanosomes has not been reported previously for any of these six compounds.
It is realized that these data are preliminary. Certainly more extensive definitive testing to determine the efficacy of one or more of these compounds must be accomplished. Also, if secondary efficacy evaluations appear promising, it is imperative that the degree of toxicity be carefully ascertained before any human trials are attempted. It should be noted that no evidence of toxicity was observed in this preliminary testing for five of these six active chemical species. Furthermore, the most active agent (WR 139 007), although tested at concentrations as high as 424 mg/kg without signs of toxicity, was curative at 13.3 mg/kg. The compound WR 177 529, which was found to exhibit toxicity, was lethal at all doses of 106 mg/kg and above. The fact that it was not curative at the next lower dose tested (although it did meet the defined criteria for being classified as an active compound) renders it an unlikely candidate for a clinically usable drug.
Perhaps most important is the finding that anti-trypanosomal activity for new classes of compounds has been found. These "hits" represent a nucleus around which chemical analogs may be synthesized. One or more of these newly synthesized compounds may demonstrate a substantial increase in anti-trypanosomal activity with no concomitant increase in toxicity to the host.
The positive relationship which apparently exists between the antitumor properties and anti-trypanosomal properties of certain compounds is poorly understood. Of 49 compounds tested, however, 6 were active, and this represents 12.2% hits. This is approximately two times as great as when other methods are employed to select compounds for testing with this same standard test (6) . In view of this, consideration of further screening of known antitumor agents from classes with previously unknown anti-trypanosomal activity seems warranted.
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